Table 2

Treatment details of the IVI regimen experienced by participants

Q7: Years of diagnosis (n=142)Proportions
Within the last year18%
1–4 years ago44%
5–10 years ago26%
>10 years ago6%
Uncertain6%
Q9: Medication (multiple selections allowed) (n=142)No of patients
Avastin (bevacizumab)17
Eylea (aflibercept)43
Lucentis (ranibizumab)45
Ozurdex (dexamethasone)4
Other1
Unknown38
Patients with multiple (>1) selections5
Q10: Tried more than one medication (n=142)Proportions
Yes33%
No37%
Uncertain30%
Q11: Frequency of injection (n=142)Proportions
Every 4–5 weeks65%
Every 6–8 weeks23%
Every 10–12 weeks6%
Every 13–16 weeks1%
Only as needed (PRN)4%
Q12: Frequency of visits (n=142)Proportions
Every 4–5 weeks65%
Every 6–8 weeks21%
Every 10–12 weeks7%
Every 13–16 weeks1%
Every six mos or more4%
Other1%
Q13: Total no of injections (n=142)Proportions
0–523%
6–1018%
11–2015%
20–5024%
>5020%
Q14: Numbing medication (multiple selections allowed) (n=142)No of patients
Numbing drops and/or numbing gel only80
Injection of numbing medicine60
Q-tips soaked with numbing medicine pushed onto your eye10
Uncertain21
Patients with multiple (>1) selections25
Q15: Use of speculum (n=142)Proportions
Yes72%
No28%
Q16: Receive injections in both eyes each visit (n=142)Proportions
Yes32%
No60%
Sometimes8%
  • IVI, intravitreal injection.